FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis
Circulation: Genomic and Precision Medicine · 2026-06 · 19 (3)
DOI: 10.1161/circgen.125.005362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2026-06. Verfasst von Taojun Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, the Chinese Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Cyclic AMP Response Element-Binding Protein, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Cardiomegaly, Fibroblast Growth Factors. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Hypertrophic cardiomyopathy (HCM) arises from genetic mutations in sarcomere proteins, resulting in major structural abnormalities and limited treatment options. Patients with HCM had reduced expression of the FGF12 (fibroblast growth factor 12), but its precise functional role remains unclear. METHODS: To explore FGF12’s function and interactions, we utilized clustered regularly interspaced short palindromic repeats-Cas9 technology in cardiomyocytes derived from human induced pluripotent stem cells-induced cardiomyocytes, as well as in other cell lines and mouse models (MYH7 R403Q/+ , MYBPC3 c790GtoA/c790GtoA , and transverse aortic constriction models). We transfected HCM or mice model with FGF12-coding sequence and FGF12-ΔNLS plasmids or adeno-associated virus 9 vectors to reduce myocardial hypertrophy. As hypertrophy progressed, we used cleavage under targets and tagmentation) sequencing and AlphaFold3 on myocardial tissues from patients and induced pluripotent stem cells-induced cardiomyocytes. To predict mitochondrial function in cardiomyocytes, we measured mitochondrial Ca 2+ concentrations and reactive oxygen species content. RESULTS: First, we observed a decrease in FGF12 expression and a difference in its subcellular localization in patients with HCM compared with healthy volunteers. In hypertrophic mouse models, injecting adeno-associated virus 9 reduced myocardial hypertrophy. FGF12 binds to calmodulin and inhibits its phosphorylation. This interaction also suppresses the expression and phosphorylation of downstream proteins, including CaMKII, ERK1/2, CREB1, and MCU. The nuclear-localization FGF12 binds to the promoter region of CREB1. FGF12 inhibits the expression of the CREB1-MCU axis expression, leading to reductions in both mitochondrial Ca 2+ concentration and mitochondrial reactive oxygen species. CONCLUSIONS: This study reveals a pathological mechanism associated with HCM linked to FGF12. FGF12, located outside the nucleus, suppresses the expression of metabolism-related genes by reducing the phosphorylation levels within the calmodulin-ERK1/2-CREB1-MCU axis. In contrast, the nuclear localization of FGF12 facilitates its binding to the promoter regions of CREB1, inhibiting CREB1 expression. This dual action maintains cardiomyocyte function and mitochondrial homeostasis. Our findings position FGF12 as a promising therapeutic target for HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, the Chinese Academy of Medical Sciences, Beijing, China (T.Z., K.Y., T.L., S.W.).
- Center of Laboratory Medicine, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, China (T.Z., K.Y.).
- Department of Cardiovascular Surgery, Fuwai Hospital, Beijing, China (S.W., Z.Z.).
- Center of Laboratory Medicine, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, China (Z.Z.).
ORCID-Profile: Taojun Zhang, Kunlun Yin, Tianjiao Li, Shuiyun Wang, Zhou Zhou
Zitieren
APA
Zhang, T., Yin, K., Li, T., Wang, S., & Zhou, Z. (2026). FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis. Circulation: Genomic and Precision Medicine, 19(3). https://doi.org/10.1161/circgen.125.005362
Vancouver
Zhang T, Yin K, Li T, Wang S, Zhou Z. FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis. Circulation: Genomic and Precision Medicine. 2026;19(3). doi:10.1161/circgen.125.005362
BibTeX
@article{Zhang2026,
author = {Zhang, Taojun and Yin, Kunlun and Li, Tianjiao and Wang, Shuiyun and Zhou, Zhou},
title = {FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis},
journal = {Circulation: Genomic and Precision Medicine},
year = {2026},
volume = {19},
number = {3},
doi = {10.1161/circgen.125.005362}
}
EUVIMED